NCT02523014 2026-04-07
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Alliance for Clinical Trials in Oncology
Phase 2 Recruiting
Clinical Trials
9 trialsNCT03297606 2026-03-27
CAPTUR
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT05538091 2025-11-26
Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
University of Pittsburgh
Phase 2 Recruiting
NCT05561634 2025-09-30
RADIOSONIC
University Hospital, Lille
Phase 2 Recruiting
NCT04341181 2025-07-25
ProTarget
Rigshospitalet, Denmark
Phase 2 Recruiting
NCT06344052 2024-09-20
To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma
Stamford Pharmaceuticals, Inc.
Phase 2 Recruiting
NCT05159245 2024-07-15
FINPROVE
Helsinki University Central Hospital
Phase 2 Recruiting
NCT04817956 2024-02-29
IMPRESS-N
Oslo University Hospital
Phase 2 Recruiting
NCT02925234 2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2 Recruiting